Symbol Name ID |
Sesn2
sestrin 2 MGI:2651874 |
Allelic Composition Genetic Background |
Annotated Term | Reference |
Lepob/Lepob Sesn2Gt(RRJ141)Byg/Sesn2Gt(RRJ141)Byg involves: 129P2/OlaHsd * C57BL/6 |
decreased fatty acid beta-oxidation | J:189021 |
hepatic steatosis | J:189021 | |
impaired glucose tolerance | J:189021 | |
increased circulating glucose level | J:189021 | |
increased liver triglyceride level | J:189021 | |
increased urine glucose level | J:189021 | |
insulin resistance | J:189021 | |
Ltbp4Gt(U3Cre)1Vmel/Ltbp4Gt(U3Cre)1Vmel Sesn2Gt(W077E06)Wrst/Sesn2Gt(W077E06)Wrst involves: 129S2/SvPas * C57BL/6 |
overexpanded pulmonary alveolus | J:160854 |
normal respiratory system phenotype | J:160854 | |
Sesn2Gt(RRJ141)Byg/Sesn2Gt(RRJ141)Byg Sesn3tm1a(EUCOMM)Wtsi/Sesn3tm1a(EUCOMM)Wtsi involves: 129P2/OlaHsd * C57BL/6N |
normal growth/size/body region phenotype | J:189021 |
impaired glucose tolerance | J:189021 | |
insulin resistance | J:189021 | |
normal liver/biliary system phenotype | J:189021 |
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 08/02/2024 MGI 6.24 |
![]() |
|